A multicentre, randomised, double-blind, placebo- and active-controlled phase I trial to evaluate the safety and efficacy of olanzapine/samidorphan in the prevention of olanzapine-induced weight gain in healthy male volunteers
Phase of Trial: Phase I
Latest Information Update: 28 May 2013
Price : $35 *
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Adverse reactions
- 28 May 2013 Results published in an Alkermes plc media release.
- 22 May 2013 Data will be presented at the 53rd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, according to an Alkermes plc media release.
- 10 Jan 2013 New trial record